Skip to main content
SpringerLink
Log in

Abirateron plus Prednison beim metastasierten kastrationsnaiven Prostatakarzinom

Bald der neue Therapiestandard?

Abiraterone plus prednisone for metastatic castration-naive prostate cancer

Soon the new standard therapy?

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. James ND et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377(4):338–351

    Article  CAS  PubMed  Google Scholar 

  2. Sweeney CJ et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. James ND et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 87(10024):1163–1177

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsmedizin Mainz, Langenbeckstraße 1, 55131, Mainz, Deutschland

    Christian Thomas

Authors
  1. Christian Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Thomas.

Ethics declarations

Interessenkonflikt

C. Thomas erhielt Honorare für Vorträge und Beratertätigkeiten sowie Reisekostenübernahme und Studienunterstützung der Firmen Janssen-Cilag, Bayer, Sanofi, Astellas, Takeda und Ipsen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Thomas, C. Abirateron plus Prednison beim metastasierten kastrationsnaiven Prostatakarzinom. Onkologe 23, 936–937 (2017). https://doi.org/10.1007/s00761-017-0284-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-017-0284-9

Search

Navigation